3/2014 (1)
Editorial ...............................................................................................................113
Přehledné články
Aleš Kolářský
K testovému pojímání falometrie................................................................................116
Fórum české neuropsychofarmakologické společnosti
Jaromír Švestka
Zastavil se vývoj nových psychofarmak? Část 3 – kognitiva..........................................135
Zprávy................................................................................................................... 147
Přečetli jsme za vás...............................................................................................150
Dopisy, ohlasy, diskuze..........................................................................................152
Nové knihy ........................................................................................................... 153
Pokyny autorům ....................................................................................................154
CONTENTS
Editorial .................................................................................................................113
Reviews
Aleš Kolářský
Comment on phallometry as a test method ................................................................116
Forum of the Czech Neuropsychopharmacological Society
Jaromír Švestka
Has the development of new psychopharmacological agents stopped?
Part iii – cognitive enhancers......................................................................................135
News ......................................................................................................................147
We have read for you.............................................................................................150
Communication.......................................................................................................152
New Books ..............................................................................................................153
Instructions for contributors ....................................................................................154
